Annual report pursuant to Section 13 and 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.23.1
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Segment
shares
Dec. 31, 2021
USD ($)
shares
Organization And Summary Of Significant Accounting Policies [Line Items]    
Accumulated deficit $ (444,768) $ (352,050)
Cash, cash equivalents, and marketable securities 61,000  
Restricted cash included in Other assets $ 2,489 $ 3,668
Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other assets Other assets
Impairment of long lived assets $ 0 $ 0
Warrants issued | shares 0 0
Reportable segment | Segment 1  
ASU No. 2021-10    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Change In Accounting Principle Accounting Standards Update Adopted true  
Change In Accounting Principle Accounting Standards Update Adoption Date Jan. 01, 2022  
Change In Accounting Principle Accounting Standards Update Immaterial Effect true  
Patents    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Amortization expense $ 100 $ 100
Estimated expense, next twelve months 100  
Estimated expense, year two 100  
Estimated expense, year three 100  
Estimated expense, year four 100  
Impairments 400  
Other Assets    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Gross value of patents $ 700 $ 1,100
Leasehold Improvements | Minimum    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Property and equipment, estimated useful lives 3 years  
Leasehold Improvements | Maximum    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Property and equipment, estimated useful lives 7 years  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 13.00% 34.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Vertex Pharmaceuticals Inc    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 0.00% 48.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Bristol Myers Squibb    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 87.00% 18.00%
K2 Loan and Security Agreement    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Borrowings $ 35,000 $ 35,000
Maturity date Jun. 01, 2024